2024-513660-26-00RecruitingPhase 2
A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Aug 2026
Brief summary (registry, in English)
The main objective of the study is to evaluate the efficacy of multi-factor intervention in high risk subjects in terms of inflammatory inflammation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 2000 (estimated)
- First submitted
- 19 Jun 2024
- Start date
- 6 Aug 2024
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Diseases
- Lung cancer
- EU CT number
- 2024-513660-26-00
- EudraCT number
- 2016-003036-20
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 2000
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for heavy smokers aged 55 to 75 who can have yearly chest CT screening for lung cancer and can use the Internet.
- Age
- 55 to 75 years
- Sex
- All sexes
- Disease stage
- Heavy smokers with no tumors in the last 5 years. They must be able to have yearly chest CT screening.
- Earlier treatment
- People on long-term treatment with cardioASA or other anti-clotting or anti-coagulant drugs cannot join. People treated with methotrexate cannot join.
Main reasons for not taking part
- Hypersensitivity to acetylsalicylic acid, salicylates or the tablet ingredients
- Serious psychiatric problems
- Abuse of alcohol or other substances, even in the past
- Chronic treatment with cardioASA or other anti-clotting or anti-coagulant drugs, or treatment with methotrexate
- Severe long-term illness, such as severe lung, kidney, liver or heart failure
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic treatment with cardioASA, or other anti-clotting or anti-coagulant drugs (for example: heparin, dicumarol)
- Treatment with methotrexate
Other illness
- Serious psychiatric problems
- History of asthma induced by the administration of salicylates or substances to similar activity, particularly non-steroidal antiinflammatory drugs
- Gastroduodenal ulcer
- Severe chronic pathology (eg: severe respiratory and / or renal and / or hepatic and / or cardiac insufficiency)
- Severe kidney failure
Lab values
- Hypersensitivity to acetylsalicylic acid, salicylates or any of the excipients (excipients: cellulose powder, corn starch; coating: copolymers of methacrylic acid, sodium lauryl sulfate, polysorbate 80, talc, triethyl citrate)
Other
- Abuse of alcohol or other substances (even before)
- Existing Mastocytosis
- Hemorrhagic diathesis
Who the study is looking for
- Age between 55 and 75 years
- Heavy smoker
- Eligibility to screening with annual chest CT
- Availability and ability to use the Internet via PC, tablet or smartphone
- Ability to understand the project to which you intend to participate
- No tumors in the last 5 years
- Signature of informed consent for enrollment in the study and for the processing of personal data
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.